Aprea reports first partial response for APR-1051; raises $5.6M in private placement

On January 28, 2026, Aprea Therapeutics, Inc. (the “ Company ”) entered into a securities purchase agreement (the “ Purchase Agreement ”) with certain accredited investors (the “ Purchasers ”), pursuant to which the Company agreed to issue and sell to the Purchasers, and the Purchasers agreed to purchase from the Company (i) 6,288,857 shares (the “ Private Placement Shares ”) of the Company’s Common Stock, par value $0.001 per share (“ Common Stock ”) or pre-funded Common Stock purchase warrants (the “ Pre-Funded Warrants ”) in lieu thereof, and (ii) common stock purchase warrants to purchase up to 6,288,857 shares of Common Stock (the “ Warrant Shares ”) at an exercise price of $0.765 per share (the “ Common Warrants ” and together with the Pre-Funded Warrants, the “ Warrants ”). The combined effective offering price of each Private Placement Share or Pre-Funded Warrant and accompanying Common Warrant to be issued is $0.89 and represents the “ Minimum Price ” in accordance with Nasdaq

In connection with the Private Placement, the Company and the Purchasers entered into a Registration Rights Agreement, dated January 29, 2026 (the “ Registration Rights Agreement ”), providing for the registration for resale of Private Placement Shares along with the shares of Common Stock underlying the Pre-Funded Warrants and Common Warrants that are not then registered on an effective registration statement, pursuant to a registration statement (the “ Registration Statement ”) to be filed with the Securities and Exchange Commission (the “ SEC ”) on or prior to the 60 th day after the Closing Date.